Key result
Metabolic syndrome in type 2 diabetes patients was associated with significantly higher TAFIa/ai antigen levels compared to healthy controls (156.6 vs 104.1 ng/dl; P=0.005).
Why the study?
Are TAFIa/ai antigen levels elevated in patients with metabolic syndrome and type 2 diabetes mellitus compared to healthy controls?
Case-Control (n=55)
Are TAFIa/ai antigen levels elevated in patients with metabolic syndrome and type 2 diabetes mellitus compared to healthy controls?
Absolute Event Rate: 156.6% vs 104.1%
p-value: p=0.005
TAFIa/ai levels are significantly elevated in patients with metabolic syndrome and correlate with the number of metabolic risk components, suggesting a potential indicator of atherosclerotic tendency.
Elevated TAFIa/ai may mark prothrombotic tendency in metabolic syndrome with diabetes; hypothesis-generating and should not yet change practice.
Thrombin activatable fibrinolysis inhibitor (TAFI) is an important procoagulant factor. Patients with metabolic syndrome (MetS) also have an elevated procoagulant status. However, TAFI and its association with MetS are still not well known. We aimed to investigate TAFI in type 2 diabetes mellitus patients with MetS. We enrolled a total of 55 patients who had MetS (n = 30) and 25 healthy controls. MetS was diagnosed using National Cholesterol Education Program Adult Treatment Panel III criteria. We measured activated and inactivated TAFI (TAFIa/ai) antigen in plasma samples using a commercially available ELISA kit (Imubind TAFIa/ai antigen ELISA; American Diagnostica Inc., Stamford, Connecticut, USA). TAFIa/ai levels were then evaluated for links to MetS parameters. Mean TAFIa/ai levels were 156.6 ± 66.9 ng/dl in patients with MetS and 104.1 ± 60.3 ng/dl in the control group (P = 0.005). None of the MetS parameters, including blood pressure, fasting plasma glucose, waist circumference, triglycerides or high-density lipoprotein cholesterol (HDL-C) levels were correlated with TAFIa/ai levels. However, TAFIa/ai level had a strong correlation with the number of metabolic risk components, which increased proportionally when MetS parameters were over three. When there were increased numbers of MetS risk components, we detected a rise in TAFIa/ai levels. TAFIa/ai levels could be an indicator of atherosclerotic tendency in patients with MetS.
No takes yet. Share an insight, caveat, or question.
Güneş et al. (2013) conducted a case-control in Metabolic syndrome in type 2 diabetes mellitus (n=55). Metabolic syndrome vs. Healthy controls was evaluated on TAFIa/ai antigen levels (p=0.005). Metabolic syndrome in type 2 diabetes patients was associated with significantly higher TAFIa/ai antigen levels compared to healthy controls (156.6 vs 104.1 ng/dl; P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: